COMMUNIQUÉS West-GlobeNewswire

BlueWillow Biologics’ Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
06/11/2025
New study published in Nature Communications paves the way for next-generation pandemic preparedness, demonstrating safety and immunogenicity of adjuvanted intranasal bird flu vaccine ANN ARBOR, Mich., Nov. 06, 2025 ( [...]
arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology
06/11/2025
Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors. MUSE ® , [...]
CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.
06/11/2025
The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term, Starting with the construction of a plant in [...]
CARBIOS et Wankai New Materials, filiale du Groupe Zhink, s’engagent pour le déploiement à très grande échelle de la technologie de biorecyclage du PET de CARBIOS en Asie, avec comme première étape la construction d’une usine en Chine.
06/11/2025
Les deux Groupes se sont accordés de manière engageante sur les grands principes de leur collaboration, en vue de déployer une capacité de 1 million de tonnes à long terme, Débutant par la construction en Chine d’une [...]
8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.
06/11/2025
Ester Baiget, President & CEO: ” I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all [...]
Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow
06/11/2025
Highlights The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven [...]
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
06/11/2025
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting [...]
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of Bv100 in China
06/11/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- First healthy volunteer dosed with BV100 in China in mandatory Phase 1 trial Inclusion of Chinese clinical sites by H2 [...]
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
06/11/2025
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
BillionToOne Announces Pricing of Upsized Initial Public Offering
06/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced [...]
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
06/11/2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
05/11/2025
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash [...]
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
05/11/2025
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 [...]
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
05/11/2025
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. [...]
The Pennant Group Announces Expansion of Credit Facility
05/11/2025
EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 [...]
New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System
05/11/2025
Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology’s Kidney Week 2025 SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“ [...]
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
05/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), [...]
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
05/11/2025
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today commented on the [...]

Pages